Stock Info Nets

Independent Financial Information Made Easy

Our AI creates

The Best Stock Graphs and Charts

Youtube Subscribe Blog GamificArt

The development of Artificial Intelligence (AI) is modifying the way investments are evaluated. We programmed an artificial intelligence (A.I.) to summarize the whole internet. Whether you’re trying to make money investing online, making financial decisions or just getting informed about Wall Street, this page is a way to get informed without reading hundred of pages. Our stock market summary graphs are produced using machine learning, an unbiased view to capture what internet is saying. Usually, the AI reads several hundred pages and summarize it to a short text and several charts.

General Description

SCYNEXIS

Youtube Subscribe

...

Ticker: SCYX

Sector: Pharmaceuticals

SCYNEXIS, Inc. develops products for the treatment of fungal infections in the United States. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the. treatment of various fun.
...
...
Extended Summary

SCYNEXIS

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Related Results

...
December 23, 2023 10:43 (London Time)

SCYNEXIS

Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. The firm reminds investors of the January 8, 2024 deadline to seek th…
Sector: Pharmaceuticals
Ticker: SCYX
Sentiment: 0.6705
MarketCap: 69,578,584.0
High: 1.92 Low: 1.82

Open: 1.87 Close: 1.86 Change: -0.01

Read more →
...
July 11, 2023 10:56 (London Time)

SCYNEXIS

SCYNEXIS (SCYX) announced an exclusive license agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets) The milestone payment follows a developmen…
Sector: Pharmaceuticals
Ticker: SCYX
Sentiment: 0.8519
MarketCap: 103,344,360.0
High: 2.88 Low: 2.79

Open: 2.8 Close: 2.83 Change: 0.03

Read more →
Search
Happening Now
Categories